On November 1, Dr. Zachary Grinspan (Chief of Child Neurology at Weill Cornell (NY) and Principal Investigator of the Volāre Study) lead a community webinar. Read the transcript of the meeting here.

Join the Volāre Study: https://redcap.link/MEF2C_WCM_registry
Donate to the Volāre Study: https://www.gofundme.com/f/global-steps-for-mchs

In September 2025, the FDA updated the leucovorin tablet label to include its use for symptoms linked to cerebral folate deficiency in autism. Although the supporting data is still preliminary and not yet conclusive, this marks an encouraging step forward for families exploring new treatment options!

You might be wondering how leucovorin fits into the picture with autism. While the exact link isn't crystal clear yet and researchers are still digging deeper, some studies suggest it could help, especially for children with autism who also have low folate levels in their brains. I’ll try to explain this as simply as possible.

When you receive a diagnosis of MEF2C haploinsufficiency syndrome, you likely underwent genetic testing. There are a few different types of genetic tests that could have led to a diagnosis: a chromosomal microarray, epilepsy gene panel, or whole exome or whole genome sequencing. For each type of testing, there could be different “flavors” of results that could come up.

Finding it hard to understand and explain the role of MEF2C in the human cell and what MCHS means? We've created an explanation just for you, with just the right amount of science-speak for the everyday parent and caregiver.

Introducing our new blog, CHIRP. We started CHIRP to provide parents, caregivers, scientists, and medical and therapeutic providers with additional information helpful to our collective journey towards effective treatments for kids with MCHS.